Emergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo Therapeutics
Emergent BioSolutions Inc. (NYSE:EBS) today announced that, as a result of the completion of the spin-off of Aptevo Therapeutics, the conversion rate for the company’s 2.875% Convertible Senior...
CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune Globulin
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised a contract option valued at $11.6 million over 12 months under contract...
Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2016...
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares...
Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 4, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2016, provide an...
Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock
In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc. (NYSE:EBS) of one share of Aptevo common stock for every two...
Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program for up to $50 million of the...
Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Registration Statement on Form 10 filed by Aptevo Therapeutics Inc. has been declared effective by the U.S. Securities and Exchange...
Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one...
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research...
U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax Vaccines
Emergent BioSolutions Inc. (NYSE:EBS) today announced that on June 21, 2016, the U.S. Department of Health and Human Services (HHS) issued two solicitation notices with respect to the development and...
FDA Completes Pre-Approval Inspection of Emergent BioSolutions’ Large-Scale Manufacturing Facility for BioThrax
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) of Building 55, the company’s facility for...